Farallon Capital Management’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Farallon Capital Management's AVTX Position: Q3 2026 in Review
Farallon Capital Management increased its Avalo Therapeutics (AVTX) stake by 59% in Q3 2026, buying an estimated $27.2M and bringing the position to 3,974,000 shares worth $60.9M. The position accounts for 0.26% of the portfolio, ranked #42.
Farallon Capital Management first reported a position in AVTX in Q1 2026 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Farallon Capital Management held 3,974,000 shares of Avalo Therapeutics worth $60.9M as of Q3 2026.
- Farallon Capital Management bought 1,476,000 Avalo Therapeutics shares in Q3 2026, an estimated $27.2M.
- Avalo Therapeutics made up 0.26% of Farallon Capital Management's portfolio in Q3 2026, its #42 holding.
- Farallon Capital Management first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Farallon Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.